Zai Lab

Zai Lab Net Debt / EBITDA

The Net Debt to EBITDA of Zai Lab (ZLAB) as of Oct 26, 2026 is 2.14. In the previous year, Net Debt to EBITDA was 2.27 — a change of -5.60% (lower).

Net Debt / EBITDA

2.14

YoY

-5.60%

Last updated:

Net Debt to EBITDA of Zai Lab is 2025 2.14 . Net Debt to EBITDA of Zai Lab was 2024 2.27 . It decreases by -5.60% lower compared to the previous year.

The Zai Lab Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
1.83 USD
Jan 1, 2019
1.30 USD
Jan 1, 2020
3.92 USD
Jan 1, 2021
2.00 USD
Jan 1, 2022
2.48 USD
Jan 1, 2023
2.18 USD
Jan 1, 2024
2.27 USD
Jan 1, 2025
2.14 USD
The Zai Lab Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
2.14-5.60%
2.27+4.02%
2.18-11.95%
2.48+23.56%
2.00-48.80%
3.92+200.05%
1.30-28.76%
1.83-104.35%
-42.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd, based in Pudong, China, is a biopharmaceutical company operating in the Health Care sector. It develops and commercializes innovative treatments for oncology, immunology, neuroscience, and infectious diseases. The company offers products such as Zejula for ovarian cancer, VYVGART for myasthenia gravis, NUZYRA for bacterial infections, Optune for brain tumors, Qinlock for gastrointestinal tumors, Xacduro for bacterial pneumonia, and Augtyro for lung cancer. Zai Lab collaborates with leading pharmaceutical firms including Pfizer and Amgen. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

Net Debt to EBITDA of Zai Lab is 2.14 in 2025.

Net Debt to EBITDA of Zai Lab changed from 2.27 to 2.14, representing a -5.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Zai Lab since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Zai Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Zai Lab

All Key Metrics — Zai Lab